检索结果 - Daniel DiPrimeo
- Showing 1 - 3 results of 3
-
1
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial 由 Claire F. Friedman, Anishka D'souza, Diana Bello Roufai, Anna V. Tinker, Maria J. de Miguel, Valentina Gambardella, Jonathan W. Goldman, Sherene Loi, Michelle Melisko, Ana Oaknin, Iben Spanggaard, Geoffrey I. Shapiro, Adam C. ElNaggar, Stefano Panni, Vignesh Ravichandran, Aimee Frazier, Daniel DiPrimeo, Lisa D. Eli, David B. Solit
出版 2024Artigo -
2
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial 由 Frankie A. Holmes, Beverly Moy, Suzette Delaloge, Stephen Chia, Bent Ejlertsen, Janine Mansi, Hiroji Iwata, Michael Gnant, Marc Buyse, Carlos H. Barrios, Tajana Silovski, Robert Šeparović, Anna Bashford, Ángel Guerrero Zotano, Neelima Denduluri, Debra A. Patt, Erhan Gökmen, Ira Gore, John W. Smith, Sibylle Loibl, Norikazu Masuda, Z. Tomasevic, Katarína Petráková, Daniel DiPrimeo, Alvin Wong, Miguel Martín, Arlene Chan
出版 2023Artigo -
3
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers 由 James J. Harding, Sarina A. Piha‐Paul, Ronak Shah, Jessica Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Braña, Víctor Moreno, Mitesh J. Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Mónica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardière, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selçuklu, Michael F. Berger, Lisa D. Eli, Funda Meric‐Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou‐Alfa
出版 2023Artigo
相关主题
Breast cancer
Cancer
Internal medicine
Medicine
Neratinib
Oncology
Trastuzumab
Adjuvant
Adjuvant therapy
Adverse effect
Alternative medicine
CDKN2A
Cancer research
Cartography
Cervical cancer
Clinical endpoint
Clinical trial
Cohort
Double blind
Geography
Pathology
Pertuzumab
Placebo
Summit
Tolerability